TGTX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- TG Therapeutics announces publication of a five-year comparative analysis of BRIUMVI versus ocrelizumab and ofatumumab in relapsing multiple sclerosisOct 12, 2026
- TG Therapeutics initiated a Phase 2 trial of BRIUMVI in treatment-resistant schizophreniaJul 8, 2026
- TG Therapeutics reported positive Phase 1 results for subcutaneous BRIUMVIJun 3, 2026
- TG Therapeutics reports positive topline results from Phase 3 ENHANCE trialMay 28, 2026
- TG Therapeutics completed enrollment in its Phase 3 trial of subcutaneous BRIUMVIApr 15, 2026